Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8984494 | 1.00 | ACE2 (0.55) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL8984408 | 1.00 | ACE2 (0.55) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL4451173 | 1.00 | ACE2 (0.55) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL3685397 | 1.00 | ACE2 (0.55) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL8984664 | 1.00 | ACE2 (0.55) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL16536902 | 1.00 | ACE2 (0.55) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL8984582 | 1.00 | ACE2 (0.55) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL5074983 | 1.00 | ACE2 (0.55) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL8230933 | 1.00 | ACE2 (0.55) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL1875589 | 1.00 | ACE2 (0.55) | ACE2BLMLTA4HGABRR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104126012-A | Bioconversion process for producing nylon-7, nylon-7,7 and polyesters | INVISTA TECH SARL | 2014-10-29 | — | — | CN | disclosed |
| CN-103896860-A | Zinc binding group-containing irreversible EGFR inhibitors | TONGHUAJIDA MEDICINE CO LTD | 2014-07-02 | — | — | CN | disclosed |
| US-20110105417-A1 | Drug Conjugates | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2011-05-05 | — | — | US | disclosed |
| WO-2009158633-A1 | DRUG CONJUGATES | CURATORS OF THE UNIVERSITY OF MISSOURI ON BEHALF OF THE UNIVERSITY OF MISSOURI-KANSAS CITY (US) | 2009-12-30 | — | — | WO | disclosed |
| CN-101189277-A | Method for producing an aqueous polymer dispersion | BASF AG (DE) | 2008-05-28 | — | — | CN | disclosed |
| EP-0910351-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0907666-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-14 | — | — | EP | disclosed |
| US-5830936-A | THERMAL STABILIZERS FOR POLYOLEFINS AND ENGINEERING PLASTICS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-11-03 | — | — | US | disclosed |
| WO-1997049736-A2 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049387-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| EP-0711746-A1 | Process for preparing hydroxycarboxylic acids | UNILEVER PLC (GB) | 1996-05-15 | — | — | EP | disclosed |
| US-5502226-A | SELECTIVE REDUCTION OF DIKETONE TO KETO ACIDS USING HYDROGEN IN THE PRESENCE OF BASE | ELIZABETH ARDEN CO., DIVISION OF CONOPCO, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| CN-1024659-C | Phenol derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-05-25 | — | — | CN | disclosed |
| CN-1032001-A | The manufacturing of phenol derivatives and application | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1989-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105417-A1 | Drug Conjugates | ABCB1, SLCO2B1, ABCG2 | ACE2 3440/4885BLM 3779/4885LTA4H 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.